Component

AKT catalytic output in human U2OS cells

AKT catalytic output in human U2OS cells. Species, exposure and limitations are retained in each linked claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Reduced phosphorylation of the AKT substrate beta-catenin at S552 indicated lower AKT output despite increased AKT T308/S473 phosphorylation.

    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/sulforaphane-research/31409554.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5486f97c1271a771620cdf2e6245a54ff63f3f56b3eb884f201fda9882ec947b", "start_char": 0, "end_char": 1778, "text_sha256": "5486f97c1271a771620cdf2e6245a54ff63f3f56b3eb884f201fda9882ec947b"}
    experimental_model
    Human cell experiments with CRISPR NRF2 deletion
    exposure
    Concentration- and time-dependent sulforaphane treatment
    limitations
    Preclinical cancer-cell signaling; AKT phosphorylation did not reliably represent catalytic output. Not a human longevity or autophagy trial.
    nutrient_topic
    Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. · Sulforaphane / SFN, stereochemistry specified per study
    organism
    Human U2OS osteosarcoma cells and NRF2-knockout counterpart
    plain_language
    An activation marker and the enzyme output moved in different directions.
    primary_references
    [sulforaphane-p31409554] The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner. (2021). https://pubmed.ncbi.nlm.nih.gov/31409554/ DOI: 10.1016/j.phymed.2019.153062
    tissue_or_cell_type
    HDAC6, AKT and mTOR signaling

    Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17) · lines 658–669

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human cell experiments with CRISPR NRF2 deletion · source_derived_draft · unverified_draft

    ### sulforaphane-akt-output Reduced phosphorylation of the AKT substrate beta-catenin at S552 indicated lower AKT output despite increased AKT T308/S473 phosphorylation. Condition category: normal nutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. plain_language: An activation marker and the enzyme output moved in different directions. organism: Human U2OS osteosarcoma cells and NRF2-knockout counterpart tissue_or_cell_type: HDAC6, AKT and mTOR signaling experimental_model: Human cell experiments with CRISPR NRF2 deletion limitations: Preclinical cancer-cell signaling; AKT phosphorylation did not reliably represent catalytic output. Not a human longevity or autophagy trial. exposure: Concentration- and time-dependent sulforaphane treatment evidence_span: {"source_cache": "artifacts/sulforaphane-research/31409554.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5486f97c1271a771620cdf2e6245a54ff63f3f56b3eb884f201fda9882ec947b", "start_char": 0, "end_char": 1778, "text_sha256": "5486f97c1271a771620cdf2e6245a54ff63f3f56b3eb884f201fda9882ec947b"} [sulforaphane-p31409554] The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner. (2021). https://pubmed.ncbi.nlm.nih.gov/31409554/ DOI: 10.1016/j.phymed.2019.153062
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards